Weight Programs Pair GLP-1 Drugs With Coaching

WW's clinical subscriptions grew 48% this quarter as its behavioral program shrank, showing medication-linked weight care gaining ground.

Updated on Nov. 6, 2026 in Weight Loss

Weight Programs Pair GLP-1 Drugs With Coaching

Live Poll

Would you pay for a weight-loss program if you already take GLP-1 medication?

WW International reported third-quarter 2026 earnings of $1.51 per share, beating the 66-cent Wall Street estimate, even as revenue fell 11.2% year over year to $152.9 million. Shares fell 2.65% to $12.50 in premarket trading, and the results matter most for U.S. readers tracking weight-management programs that now combine behavioral coaching with prescription GLP-1 medications.

Why it matters

The quarter shows a shift in how a major commercial weight-loss program is structured: clinical subscriptions grew while behavioral subscribers declined, reflecting growing demand for programs built around GLP-1 medications. For readers, this signals that more weight-management options may now pair medication with nutrition and coaching support, though the company's own results show a mixed picture.

These figures come from WW International's own third-quarter 2026 financial report, not an independent clinical study. Clinical subscription revenue rose 48% to $38 million, while behavioral subscription revenue fell 22% to $113.9 million.

The players

WW International

A weight-management company offering digital behavioral coaching, nutrition programs and clinical support for patients using GLP-1 medications.

The details

WW combines digital behavioral coaching, nutrition guidance and community support with its clinical offering, which supports patients using GLP-1 medications. Management said Core+ enrollment in its GLP-1 Success Program has more than doubled since January, and the company plans to focus on nutrition, behavioral coaching and community support regardless of where customers obtain their medications. Management linked the quarterly decline in clinical subscribers to subscription renewals and changes in marketing spending. Marketing expenses fell to $33.1 million from $48.4 million a year earlier.

January 2026: Core+ GLP-1 Success Program enrollment began doubling.
June 2026: Clinical subscribers stood at 197,000 before the quarterly decline.
Q3 2026: Third-quarter results were reported Thursday, beating estimates.
Fourth quarter 2026: Marketing spending is set to increase ahead of the 2027 peak season.
2027: Target year for sustainable, profitable growth.

Health Landscape

The shift reflects broader demand for weight-management care built around GLP-1 medications rather than behavioral programs alone. Clinical subscriptions growing while behavioral enrollment shrinks shows how commercial weight-loss providers are repositioning around prescription treatment.

If you are managing weight with a medication, these results suggest some programs now pair prescriptions with nutrition and coaching support, which may be worth asking your doctor about. Any decision to start, stop, or change a medication should be made with your physician.

The takeaway

Weight-management programs are increasingly combining medication with behavioral support. If you are considering a GLP-1 medication, discuss with your physician whether pairing it with nutrition and coaching support fits your goals.

What happens next

Marketing spending will increase in the fourth quarter as the company prepares for its 2027 peak season, and the company has set a 2027 target for sustainable, profitable growth.